Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 and TB-500: Research Comparison

The table below synthesizes the primary differences in structure, mechanism, and research application between BPC-157 and TB-500 to guide peptide selection for specific experimental models. Molecular Weight 1,419 Da (15 amino acids) 4,963 Da (43 amino acids) B

This comparison does not assign a generated winner or score.

  • The table below synthesizes the primary differences in structure, mechanism, and research application between BPC-157 and TB-500 to guide peptide selection for specific experimental models.
  • Molecular Weight
  • 1,419 Da (15 amino acids)
  • 4,963 Da (43 amino acids)
  • BPC-157's smaller size enables faster local tissue penetration; TB-500's larger structure correlates with longer systemic half-life
  • Primary Mechanism
  • VEGF upregulation, angiogenesis, nitric oxide pathway modulation
  • Actin monomer sequestration, NF-κB downregulation, cell migration promotion
  • Non-overlapping pathways—BPC-157 is vascular-focused; TB-500 is cytoskeletal and immune-focused
  • Origin
  • Synthetic sequence from gastric protective protein BPC
  • Synthetic fragment of thymosin beta-4 (naturally occurring in most cells)
  • BPC-157 is gut-derived and acid-stable; TB-500 is immune-origin and systemically distributed
  • Blood-Brain Barrier
  • Limited to no permeability
  • Crosses BBB effectively
  • TB-500 is suitable for CNS injury models; BPC-157 is not
  • Half-Life (Preclinical)
  • 4–6 hours tissue residence
  • 10–12 hours plasma half-life
  • TB-500 requires less frequent dosing in sustained-release models
  • Optimal Tissue Types
  • Tendons, ligaments, GI mucosa, vascular-limited injuries
  • Muscle, cardiac, diffuse inflammation, systemic tissue damage
  • Match peptide to injury mechanism—vascular vs inflammatory
  • Administration Route
  • Oral, subcutaneous, intraperitoneal (acid-stable)
  • Subcutaneous, intramuscular (degrades in gastric environment)
  • BPC-157 tolerates oral routes; TB-500 requires injection
  • Typical Research Dose
  • 10–500 mcg/kg body weight
  • 5–20 mg per dose (varies by model)
  • Dose ranges are not directly comparable due to different mechanisms
More references

Related material